Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (134) 134
humans (131) 131
oncology (123) 123
colorectal cancer (76) 76
female (54) 54
male (54) 54
colorectal neoplasms - genetics (53) 53
colorectal neoplasms - drug therapy (49) 49
middle aged (46) 46
mutation (46) 46
cetuximab (45) 45
cancer (43) 43
aged (42) 42
adult (40) 40
colorectal neoplasms - pathology (37) 37
chemotherapy (30) 30
prognosis (29) 29
proto-oncogene proteins p21 (27) 27
tumors (27) 27
ras proteins - genetics (26) 26
care and treatment (25) 25
expression (25) 25
proto-oncogene proteins - genetics (25) 25
receptor, epidermal growth factor - antagonists & inhibitors (25) 25
aged, 80 and over (24) 24
disease-free survival (23) 23
metastasis (23) 23
1st-line treatment (22) 22
antibodies, monoclonal, humanized (22) 22
antineoplastic agents - therapeutic use (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
genetic aspects (22) 22
kras (22) 22
camptothecin - analogs & derivatives (21) 21
fluorouracil (21) 21
proto-oncogene proteins b-raf - genetics (21) 21
gene expression (20) 20
irinotecan (20) 20
microsatellite instability (20) 20
research (20) 20
treatment outcome (20) 20
animals (18) 18
antibodies, monoclonal - therapeutic use (17) 17
biomarkers, tumor - genetics (17) 17
mutations (17) 17
panitumumab (17) 17
trial (17) 17
colon cancer (16) 16
metastatic colorectal-cancer (16) 16
biomarkers (15) 15
digestive system diseases (15) 15
colon-cancer (14) 14
colonic neoplasms - genetics (14) 14
colorectal neoplasms - metabolism (14) 14
drug therapy (14) 14
leucovorin (14) 14
neoplasm metastasis (14) 14
neoplasm staging (14) 14
abridged index medicus (13) 13
biomarkers, tumor - metabolism (13) 13
breast-cancer (13) 13
carcinoma (13) 13
cell line, tumor (13) 13
colonic neoplasms - pathology (13) 13
colorectal-cancer (13) 13
gene copy number (13) 13
growth-factor receptor (13) 13
kaplan-meier estimate (13) 13
survival (13) 13
analysis (12) 12
camptothecin - administration & dosage (12) 12
colorectal neoplasms - mortality (12) 12
egfr (12) 12
gastroenterology & hepatology (12) 12
health aspects (12) 12
hematology, oncology and palliative medicine (12) 12
medical research (12) 12
medicine (12) 12
mice (12) 12
oxaliplatin (12) 12
patients (12) 12
phenotype (12) 12
precision medicine (12) 12
predictive value of tests (12) 12
research article (12) 12
signal transduction (12) 12
cell biology (11) 11
colorectal carcinoma (11) 11
gene expression regulation, neoplastic (11) 11
prospective studies (11) 11
receptor, epidermal growth factor - metabolism (11) 11
therapy (11) 11
biochemistry & molecular biology (10) 10
epidermal growth factor (10) 10
gene mutations (10) 10
genes (10) 10
genetics (10) 10
genetics & heredity (10) 10
proteins (10) 10
young adult (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
by De Roock, Wendy, MD and Claes, Bart, MSc and Bernasconi, David, MSc and De Schutter, Jef, MSc and Biesmans, Bart, MSc and Fountzilas, George, Prof and Kalogeras, Konstantine T, MD and Kotoula, Vassiliki, MD and Papamichael, Demetris, FRCP and Laurent-Puig, Pierre, Prof and Penault-Llorca, Frédérique, Prof and Rougier, Philippe, Prof and Vincenzi, Bruno, MD and Santini, Daniele, MD and Tonini, Giuseppe, Prof and Cappuzzo, Federico, MD and Frattini, Milo, PhD and Molinari, Francesca, PhD and Saletti, Piercarlo, MD and De Dosso, Sara, MD and Martini, Miriam, PhD and Bardelli, Alberto, Prof and Siena, Salvatore, Prof and Sartore-Bianchi, Andrea, MD and Tabernero, Josep, Prof and Macarulla, Teresa, MD and Di Fiore, Frédéric, MD and Gangloff, Alice Oden, MD and Ciardiello, Fortunato, Prof and Pfeiffer, Per, Prof and Qvortrup, Camilla, MD and Hansen, Tine Plato, MD and Van Cutsem, Eric, Prof and Piessevaux, Hubert, Prof and Lambrechts, Diether, Prof and Delorenzi, Mauro, PhD and Tejpar, Sabine, Prof
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 8, pp. 753 - 762
Summary Background Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the... 
Hematology, Oncology and Palliative Medicine | BREAST-CANCER | RESECTED COLON-CANCER | POLYMORPHISMS | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | POOR-PROGNOSIS | RESISTANCE | IRINOTECAN | GENE COPY NUMBER | SINGLE-AGENT CETUXIMAB | EGFR | Multivariate Analysis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Retrospective Studies | Cetuximab | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Proportional Hazards Models | Antineoplastic Combined Chemotherapy Protocols | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Class I Phosphatidylinositol 3-Kinases | Antibodies, Monoclonal - administration & dosage | Proto-Oncogene Proteins B-raf - genetics | Survival Analysis | ROC Curve | Aged | Biomarkers, Tumor - genetics | Mutation | Medical colleges | Molecular genetics | Oncology, Experimental | Colorectal cancer | Antibodies | Metastasis | Research | Antineoplastic agents | Viral antibodies | Antimitotic agents | Consortia | Chemotherapy | Analysis | Genetic research | Genetic aspects | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
by Sabine Tejpar and Ilhan Celik and Michael Schlichting and Ute Sartorius and Carsten Bokemeyer and Eric Van Cutsem
Journal of Clinical Oncology, ISSN 0732-183X, 10/2012, Volume 30, Issue 29, pp. 3570 - 3577
Purpose We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC)... 
PANITUMUMAB | K-RAS MUTATIONS | LEUCOVORIN | EFFICACY | ONCOLOGY | BRAF MUTATION | PHASE-III | GROWTH | OXALIPLATIN | FLUOROURACIL | MURINE FIBROBLASTS | Multivariate Analysis | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Follow-Up Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Antibodies, Monoclonal - therapeutic use | Male | Young Adult | Antibodies, Monoclonal, Humanized | Likelihood Functions | Neoplasm Metastasis | Neoplasm Invasiveness - pathology | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Cetuximab | Colorectal Neoplasms - mortality | Risk Assessment | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
by Lambrechts, Diether, Prof and Claes, Bart, MSc and Delmar, Paul, PhD and Reumers, Joke, PhD and Mazzone, Massimiliano, Prof and Yesilyurt, Betül T, MSc and Devlieger, Roland, Prof and Verslype, Chris, Prof and Tejpar, Sabine, Prof and Wildiers, Hans, Prof and de Haas, Sanne, PhD and Carmeliet, Peter, Prof and Scherer, Stefan J, MD and Van Cutsem, Eric, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 724 - 733
Summary Background No biomarkers that could guide patient selection for treatment with the anti-VEGF monoclonal antibody bevacizumab have been identified. We... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | BREAST-CANCER | POLYMORPHISMS | ONCOLOGY | ANTI-ANGIOGENIC THERAPY | PACLITAXEL PLUS BEVACIZUMAB | COMBINATION | ASSOCIATION | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Proportional Hazards Models | Molecular Sequence Data | Male | Treatment Outcome | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Randomized Controlled Trials as Topic | Pancreatic Neoplasms - drug therapy | Clinical Trials, Phase III as Topic | Base Sequence | Angiogenesis Inhibitors - therapeutic use | Biomarkers | Adult | Female | Aged | Polymorphism, Single Nucleotide | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Vascular Endothelial Growth Factor A - physiology | Vascular Endothelial Growth Factor Receptor-1 - genetics | Viral antibodies | Antimitotic agents | Endothelial growth factors | Analysis | Monoclonal antibodies | Antibodies | Clinical trials | Genetic research | Universities and colleges | Antineoplastic agents | Biological markers | Vascular endothelial growth factor | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
by Eric Van Cutsem and Claus-Henning Köhne and István Láng and Gunnar Folprecht and Marek P. Nowacki and Stefano Cascinu and Igor Shchepotin and Joan Maurel and David Cunningham and Sabine Tejpar and Michael Schlichting and Angela Zubel and Ilhan Celik and Philippe Rougier and Fortunato Ciardiello
Journal of Clinical Oncology, ISSN 0732-183X, 05/2011, Volume 29, Issue 15, pp. 2011 - 2019
Purpose The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was... 
PANITUMUMAB | RESISTANCE | FLEX | THERAPY | ONCOLOGY | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Neoplasm Metastasis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Cetuximab | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - therapeutic use | Proto-Oncogene Proteins - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The consensus molecular subtypes of colorectal cancer
by Guinney, Justin and Dienstmann, Roigo and Wang, Xin and de Reyniès, Aurélien and Schlicker, Aneas and Soneson, Charlotte and Marisa, Laetitia and Roepman, Paul and Nyamundanda, Gift and Angelino, Paolo and Bot, Brian M and Morris, Jeffrey S and Simon, Iris M and Gerster, Sarah and Fessler, Evelyn and de Sousa E Melo, Felipe and Missiaglia, Edoardo and Ramay, Hena and Barras, David and Homicsko, Krisztian and Maru, Dipen and Manyam, Ganiraju C and Broom, Bradley and Boige, Valerie and Perez-Villamil, Beatriz and Laderas, Ted and Salazar, Ramon and Gray, Joe W and Hanahan, Douglas and Tabernero, Josep and Bernards, Rene and Friend, Stephen H and Laurent-Puig, Pierre and Medema, Jan Paul and Sadanandam, Anguraj and Wessels, Lodewyk and Delorenzi, Mauro and Kopetz, Scott and Vermeulen, Louis and Tejpar, Sabine
Nature medicine, ISSN 1078-8956, 2015, Volume 21, Issue 11, pp. 1350 - 1356
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene... 
MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | III COLON-CANCER | MICROSATELLITE INSTABILITY | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHENOTYPE | CLASSIFICATION | TUMORS | CELL BIOLOGY | RESPONSES | RECTAL-CANCER | MUTATION | GROWTH | ras Proteins - genetics | Microsatellite Instability | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Gene Expression Regulation, Neoplastic | Gene Expression Profiling | Information Dissemination | Neovascularization, Pathologic - pathology | DNA Methylation | Carcinoma - pathology | Proto-Oncogene Proteins - genetics | Colorectal Neoplasms - classification | DNA Copy Number Variations - genetics | Mutation - genetics | Consensus | Phenotype | Transforming Growth Factor beta - genetics | Wnt Signaling Pathway - genetics | Proto-Oncogene Proteins B-raf - genetics | Genes, myc - genetics | CpG Islands | Carcinoma - genetics | Neovascularization, Pathologic - genetics | Carcinoma - classification | Colorectal Neoplasms - pathology | Care and treatment | Usage | MicroRNA | Colorectal cancer | Liquid chromatography | Research | Gene expression | Transforming growth factors | Genotype & phenotype | Genomics | Index Medicus | Classificació de tumors | Oncologia | Oncology | Càncer colorectal | Tumors classification
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
by Arnaud D. Roth and Sabine Tejpar and Mauro Delorenzi and Pu Yan and Roberto Fiocca and Dirk Klingbiel and Daniel Dietrich and Bart Biesmans and György Bodoky and Carlo Barone and Enrique Aranda and Bernard Nordlinger and Laura Cisar and Roberto Labianca and David Cunningham and Eric Van Cutsem and Fred Bosman
Journal of Clinical Oncology, ISSN 0732-183X, 01/2010, Volume 28, Issue 3, pp. 466 - 474
Purpose Mutations within the KRAS proto-oncogene have predictive value but are of uncertain prognostic value in the treatment of advanced colorectal cancer. We... 
CETUXIMAB | KIRSTEN RAS MUTATIONS | METAANALYSIS | K-RAS | ONCOLOGY | MICROSATELLITE INSTABILITY | POOR SURVIVAL | METHYLATOR PHENOTYPE | CARCINOMA | TP53 | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Prognosis | Prospective Studies | Humans | Middle Aged | Colonic Neoplasms - diagnosis | Male | Proto-Oncogene Proteins - genetics | Young Adult | Adenocarcinoma - diagnosis | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Adolescent | Adult | Female | Adenocarcinoma - genetics | Aged | Mutation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
by Hubert Piessevaux and Marc Buyse and Michael Schlichting and Eric Van Cutsem and Carsten Bokemeyer and Steffen Heeger and Sabine Tejpar
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 30, pp. 3764 - 3775
Purpose Early tumor shrinkage (ETS) is associated with long-term outcome in patients with chemorefractory metastatic colorectal cancer (mCRC) receiving... 
SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | ONCOLOGY | KRAS | BRAF | FLUOROURACIL | N9741 | CHEMOTHERAPY | Colorectal Neoplasms - mortality | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Sensitivity and Specificity | Adult | Female | ROC Curve | Aged | Cetuximab | Colorectal Neoplasms - pathology | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
by Van Cutsem, Eric and Köhne, Claus-Henning and Hitre, Erika and Zaluski, Jerzy and Chang Chien, Chung-Rong and Makhson, Anatoly and D'Haens, Geert and Pintér, Tamás and Lim, Robert and Bodoky, György and Roh, Jae Kyung and Folprecht, Gunnar and Ruff, Paul and Stroh, Christopher and Tejpar, Sabine and Schlichting, Michael and Nippgen, Johannes and Rougier, Philippe
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 14, pp. 1408 - 1417
Previous trials have shown that the combination of fluorouracil-based chemotherapy and cetuximab is active when used as salvage treatment in patients with... 
TRIAL | K-RAS MUTATIONS | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | PLUS IRINOTECAN | PHASE-III | OXALIPLATIN | KRAS | FLUOROURACIL | COMBINATION | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Young Adult | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Cetuximab | Camptothecin - analogs & derivatives | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Genes, ras | Usage | Care and treatment | Leucovorin | Health aspects | Colorectal cancer | Fluorouracil | Studies | Chemotherapy | Clinical trials | Monoclonal antibodies | Radiation therapy | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
by Budinska, Eva and Popovici, Vlad and Tejpar, Sabine and D'Ario, Giovanni and Lapique, Nicolas and Sikora, Katarzyna Otylia and Di Narzo, Antonio Fabio and Yan, Pu and Hodgson, John Graeme and Weinrich, Scott and Bosman, Fred and Roth, Arnaud and Delorenzi, Mauro
The Journal of Pathology, ISSN 0022-3417, 09/2013, Volume 231, Issue 1, pp. 63 - 76
The recognition that colorectal cancer ( CRC ) is a heterogeneous disease in terms of clinical behaviour and response to therapy translates into an urgent need... 
histopathology | colorectal cancer | gene expression | molecular heterogeneity | Histopathology | Molecular heterogeneity | Gene expression | Colorectal cancer | II COLON-CANCER | STEM-CELLS | MICROSATELLITE INSTABILITY | INDIAN HEDGEHOG | PATHOLOGY | STAGE-II | BREAST-CANCER | BIOINFORMATICS | MESSENGER-RNA | ONCOLOGY | POOR-PROGNOSIS | DIFFERENTIATION | Colorectal Neoplasms - mortality | Adenocarcinoma - pathology | Prognosis | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Kaplan-Meier Estimate | Gene Expression Profiling - methods | Male | Gene Dosage | Loss of Heterozygosity | Genetic Heterogeneity | Female | Adenocarcinoma - genetics | Mutation | Colorectal Neoplasms - pathology | Neoplasm Proteins - genetics | Gene Expression Regulation, Neoplastic - physiology | Adenocarcinoma - mortality | Genetic aspects | Cancer | Index Medicus | Original Papers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
by Hans Prenen and Jef De Schutter and Bart Jacobs and Wendy De Roock and Bart Biesmans and Bart Claes and Diether Lambrechts and Eric Van Cutsem and Sabine Tejpar
Clinical Cancer Research, ISSN 1078-0432, 05/2009, Volume 15, Issue 9, pp. 3184 - 3188
Purpose: It has been reported that activating KRAS mutations negatively affect response to anti–epidermal growth factor receptor (EGFR) monoclonal antibodies... 
cetuximab | metastatic colorectal cancer | PIK3CA | EGFR | POPULATION | ONCOGENE | THERAPY | GENE | ONCOLOGY | PATHWAY | POOR SURVIVAL | SIGNALING NETWORK | HIGH-FREQUENCY | IRINOTECAN | KRAS | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antibodies, Monoclonal, Humanized | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Adenocarcinoma - genetics | Cetuximab | Camptothecin - analogs & derivatives | Proto-Oncogene Proteins - genetics | Survival Rate | Treatment Outcome | Mutation - genetics | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Class I Phosphatidylinositol 3-Kinases | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
by De Roock, Wendy and Jonker, Derek J and Di Nicolantonio, Federica and Sartore-Bianchi, Andrea and Tu, Dongsheng and Siena, Salvatore and Lamba, Simona and Arena, Sabrina and Frattini, Milo and Piessevaux, Hubert and Van Cutsem, Eric and O’Callaghan, Chris J and Khambata-Ford, Shirin and Zalcberg, John R and Simes, John and Karapetis, Christos S and Bardelli, Alberto and Tejpar, Sabine
JAMA, ISSN 0098-7484, 10/2010, Volume 304, Issue 16, pp. 1812 - 1820
CONTEXT Patients with metastatic colorectal cancer who have KRAS codon 12– or KRAS codon 13–mutated tumors are presently excluded from treatment with the... 
MEDICINE, GENERAL & INTERNAL | IRINOTECAN | OXALIPLATIN | EFFICACY | CARCINOMA | GROWTH | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Follow-Up Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Patient Selection | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Codon | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Cetuximab | Proto-Oncogene Proteins - genetics | Treatment Outcome | Clinical Trials as Topic | Disease Progression | Survival Analysis | Aged | Colorectal Neoplasms - pathology | Genetic aspects | Gene mutations | Drug therapy | Patient outcomes | Analysis | Colorectal cancer | Drugs | Clinical trials | Patients | Medical treatment | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights